- Home
- INSM vs FTAIO Comparison
INSM vs FTAIO Comparison
Compare INSM & FTAIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- FTAIO
- Stock Information
- Founded
- INSM 1988
- FTAIO N/A
- Country
- INSM United States
- FTAIO United States
- Employees
- INSM N/A
- FTAIO 170
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- FTAIO Misc Corporate Leasing Services
- Sector
- INSM Health Care
- FTAIO Industrials
- Exchange
- INSM Nasdaq
- FTAIO Nasdaq
- Market Cap
- INSM 13.7B
- FTAIO N/A
- IPO Year
- INSM 2000
- FTAIO N/A
- Fundamental
- Price
- INSM $81.01
- FTAIO $25.42
- Analyst Decision
- INSM Strong Buy
- FTAIO
- Analyst Count
- INSM 16
- FTAIO 0
- Target Price
- INSM $84.29
- FTAIO N/A
- AVG Volume (30 Days)
- INSM 2.0M
- FTAIO N/A
- Earning Date
- INSM 02-20-2025
- FTAIO N/A
- Dividend Yield
- INSM N/A
- FTAIO N/A
- EPS Growth
- INSM N/A
- FTAIO N/A
- EPS
- INSM N/A
- FTAIO N/A
- Revenue
- INSM $342,958,000.00
- FTAIO N/A
- Revenue This Year
- INSM $19.74
- FTAIO N/A
- Revenue Next Year
- INSM $43.16
- FTAIO N/A
- P/E Ratio
- INSM N/A
- FTAIO N/A
- Revenue Growth
- INSM 22.13
- FTAIO N/A
- 52 Week Low
- INSM $21.92
- FTAIO N/A
- 52 Week High
- INSM $81.25
- FTAIO N/A
- Technical
- Relative Strength Index (RSI)
- INSM 68.75
- FTAIO 59.07
- Support Level
- INSM $74.47
- FTAIO $24.76
- Resistance Level
- INSM $80.63
- FTAIO $25.39
- Average True Range (ATR)
- INSM 2.98
- FTAIO 0.08
- MACD
- INSM 0.55
- FTAIO 0.01
- Stochastic Oscillator
- INSM 98.08
- FTAIO 97.98
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About FTAIO FTAI Aviation Ltd. 8.00% Fixed-to-Floating Rate Series B Cumulative Perpetual Redeemable Preferred Shares
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate strong and stable cash flows with the potential for earnings growth and asset appreciation.